Bulk Inquiry
RN277
- Soluble in DMSO
- MF: C31H33ClN8O2
- MW: 585.10
Description
RN277 is the first reported potent and selective LRRK2 type II kinase inhibitor with an IC50 value of 70 nM. As a type II inhibitor, RN277 stabilizes the inactive kinase conformation of LRRK2 and provides a valuable tool for investigating LRRK2 biology using a mechanism distinct from conventional type I LRRK2 inhibitors.
Leucine-rich repeat kinase 2 (LRRK2) is a multifunctional kinase implicated in Parkinson's disease, neuroinflammation, vesicle trafficking, lysosomal biology, and neuronal homeostasis. Mutations in LRRK2 represent one of the most common genetic causes of familial Parkinson's disease. RN277 enables selective interrogation of LRRK2-dependent signaling pathways and serves as an important chemical probe for studying LRRK2 kinase function, neurodegeneration, and kinase conformational biology.
Key Features
- First reported selective type II LRRK2 inhibitor
- IC50: 70 nM
- Targets the inactive conformation of LRRK2
- Distinct mechanism compared with type I LRRK2 inhibitors
- Useful chemical probe for LRRK2 biology research
Applications
- LRRK2 signaling and kinase biology research
- Parkinson's disease investigations
- Neurodegeneration and neuroinflammation studies
- Lysosomal and vesicle trafficking research
- Target validation and kinase conformational studies
More Information
| Parent CAS No. | 3091508-55-0 |
|---|---|
| Chemical Name | 1-(3-tert-Butyl-1-(1,4-tolyl)-5-pyrazolyl)-3-(3-(6-chloro-4-morpholino-1,5,7-triaza-1H-inden-3-yl)phenyl)urea |
| MFCD | N.A. |
| Short Description | LRRK2 type II inhibitor |
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 2181 | GSK 2578215A |
From $137.50 |
| 2348 | GNE 7915 |
From $121.00 |
| 2493 | LRRK2-IN-1 |
From $99.00 |
| 2546 | PF 06447475 |
From $93.50 |
